Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes

Wen Chi Chou, Shiu Feng Huang, Kun Yang Yeh, Hung Ming Wang, Mei Ying Liu, Jia Juan Hsieh, Yun Chung Cheung, John Wen Cheng Chang*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

11 Scopus citations

Abstract

Response to gefitinib is strongly associated with the status of the epidermal growth factor receptor gene. Here we report the different treatment responses in a case of lung adenocarcinoma coexpressing mutant-type gene in the primary lung mass and a wild-type gene in the metastatic bone lesions. This case demonstrated that at least two strains of tumor cells were present in a single patient. This may be one of the mechanisms of gefitinib resistance.

Original languageEnglish
Pages (from-to)523-526
Number of pages4
JournalJapanese Journal of Clinical Oncology
Volume36
Issue number8
DOIs
StatePublished - 08 2006

Keywords

  • Gene profiling, translational oncology
  • Lung cancer (diagnosis and
  • Signal transduction, EGFR mutation)
  • Staging, translational oncology

Fingerprint

Dive into the research topics of 'Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes'. Together they form a unique fingerprint.

Cite this